The phase III TULIP trial revealed that this ADC led to a significant survival benefit over SOC, in metastatic HER2-positive BC patients previously treated with anti-HER2 directed treatments (>2 lines), including T-DM1 [40]. This evidence concerns the gene ERBB2 and breast cancer.